Dashboard
Manage Tickers

MRKMerck & Co., Inc.

NYSE merck.com


$ 129.24 $ -2.26 (-1.72 %)    

Thursday, 27-Jun-2024 11:01:52 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 480.79 $ 0.81 (0.17 %)
DIA $ 392.08 $ 0.84 (0.21 %)
SPY $ 545.83 $ 0.34 (0.06 %)
TLT $ 93.56 $ 0.13 (0.14 %)
GLD $ 215.23 $ 2.65 (1.25 %)
$ 131.5
$ 131.94
$ 128.90 x 100
$ 129.27 x 100
$ 129.18 - $ 132.15
$ 97.23 - $ 134.63
7,132,729
na
333.06B
$ 0.32
$ 144.43
TBD
na
na ($ 0.02)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-03-2024 03-31-2024 10-Q
2 02-26-2024 12-31-2023 10-K
3 11-03-2023 09-30-2023 10-Q
4 08-07-2023 06-30-2023 10-Q
5 05-05-2023 03-31-2023 10-Q
6 02-24-2023 12-31-2022 10-K
7 11-03-2022 09-30-2022 10-Q
8 08-04-2022 06-30-2022 10-Q
9 05-05-2022 03-31-2022 10-Q
10 02-25-2022 12-31-2021 10-K
11 11-05-2021 09-30-2021 10-Q
12 08-09-2021 06-30-2021 10-Q
13 05-05-2021 03-31-2021 10-Q
14 02-25-2021 12-31-2020 10-K
15 11-05-2020 09-30-2020 10-Q
16 08-05-2020 06-30-2020 10-Q
17 05-06-2020 03-31-2020 10-Q
18 02-26-2020 12-31-2019 10-K
19 11-05-2019 09-30-2019 10-Q
20 08-06-2019 06-30-2019 10-Q
21 05-08-2019 03-31-2019 10-Q
22 02-27-2019 12-31-2018 10-K
23 11-06-2018 09-30-2018 10-Q
24 08-07-2018 06-30-2018 10-Q
25 05-08-2018 03-31-2018 10-Q
26 02-27-2018 12-31-2017 10-K
27 11-07-2017 09-30-2017 10-Q
28 08-08-2017 06-30-2017 10-Q
29 05-09-2017 03-31-2017 10-Q
30 02-28-2017 12-31-2016 10-K
31 11-07-2016 09-30-2016 10-Q
32 08-08-2016 06-30-2016 10-Q
33 05-09-2016 03-31-2016 10-Q
34 02-26-2016 12-31-2015 10-K
35 11-05-2015 09-30-2015 10-Q
36 08-06-2015 06-30-2015 10-Q
37 05-07-2015 03-31-2015 10-Q
38 02-27-2015 12-31-2014 10-K
39 11-10-2014 09-30-2014 10-Q
40 08-07-2014 06-30-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

fda-declines-to-approve-merck-daiichi-sankyo-partnered-lung-cancer-drug
FDA Declines To Approve Merck-Daiichi Sank...
06/27/2024 14:13:16

The FDA issued a Complete Response Letter for Daiichi Sankyo and Merck's BLA for patritumab deruxtecan targeting EGFR-mutat...

reported-earlier-fda-issues-complete-response-letter-for-daiichi-sankyo-and-mercks-lung-cancer-treatment-patritumab-deruxtecan-approval-delayed-by-fda-due-to-third-party-manufacturing-concerns
Reported Earlier, FDA Issues Complete Resp...
06/27/2024 07:13:05

The U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) for the Biologics License Application (...

beating-cancer-is-still-an-everything-but-easy-challenge-that-pharmaceutical-companies-cannot-solve-overnight
Beating Cancer Is Still An Everything-But-...
06/26/2024 15:29:20

On Tuesday, Merck Group revealed an unexpected decision to end a Phase III trial of its cancer drug Xevinapant. This move threa...

merck--companys-merck-animal-health-received-approval-of-nobivac-nxt-canine-flu-h3n2-from-us-dept-of-agriculture
Merck & Company's Merck Animal Health Rece...
06/25/2024 20:06:30

Innovative technology represents a breakthrough scientific achievement for highly contagious respiratory disease

analyst-sees-keros-therapeutics-as-next-acceleron-set-for-major-biotech-growth
Analyst Sees Keros Therapeutics As Next Ac...
06/25/2024 18:43:19

Keros Therapeutics is advancing novel therapies for hematological and cardiopulmonary disorders via TGF-β signaling regulation....

gossamer-bios-clean-safety-profile-differentiates-it-from-merck-analyst-says
Gossamer Bio's Clean Safety Profile Differ...
06/25/2024 18:39:14

Oppenheimer initiated coverage on Gossamer Bio, highlighting seralutinib's clean long-term safety profile for pulmonary art...

10-health-care-stocks-whale-activity-in-todays-session
10 Health Care Stocks Whale Activity In To...
06/25/2024 17:35:24

Core News & Articles
CORRECTION: Merck KGaA Ticker Is "MKGAF"
06/24/2024 17:06:47

5-biotech-stocks-with-key-catalysts-this-week-merck-intellia-verona-and-more
5 Biotech Stocks With Key Catalysts This W...
06/24/2024 08:51:47

Biotech investing is risk-fraught but the returns could be staggering if one chooses to take the educated approach.

gilead-sciences-faces-wall-street-speculation-about-obesity-drugs-despite-focus-on-liver-treatments
Gilead Sciences Faces Wall Street Speculat...
06/21/2024 15:42:22

Gilead Sciences faces Wall Street speculation about its potential in the obesity drug market despite its focus on liver treatme...

cantor-fitzgerald-reiterates-overweight-on-merck--co-maintains-155-price-target
Cantor Fitzgerald Reiterates Overweight on...
06/20/2024 16:59:56

Cantor Fitzgerald analyst Louise Chen reiterates Merck & Co (NYSE:MRK) with a Overweight and maintains $155 price target.

cracking-the-code-understanding-analyst-reviews-for-merck--co
Cracking The Code: Understanding Analyst R...
06/18/2024 21:00:57

competitor-analysis-evaluating-merck-amp-co-and-competitors-in-pharmaceuticals-industry
Competitor Analysis: Evaluating Merck &amp...
06/18/2024 15:00:37

covid-19-pharma-stars-continue-their-quest-to-set-new-standards-in-cancer-treatment
Covid-19 Pharma Stars Continue Their Quest...
06/18/2024 14:19:12

AstraZeneca PLC (NASDAQ: AZN) kicked off the week by receiving approval from the U.S. Food and Drug Administration for its bloc...

cantor-fitzgerald-reiterates-overweight-on-merck--co-maintains-155-price-target
Cantor Fitzgerald Reiterates Overweight on...
06/18/2024 12:08:42

Cantor Fitzgerald analyst Louise Chen reiterates Merck & Co (NYSE:MRK) with a Overweight and maintains $155 price target.

fda-approves-mercks-pneumococcal-vaccine-as-first-shot-designed-for-adults
FDA Approves Merck's Pneumococcal Vaccine ...
06/18/2024 12:05:42

The FDA has approved Merck's Capvaxive, the first pneumococcal conjugate vaccine for adults, protecting against 21 strains ...

Core News & Articles
FDA Approves CAPVAXIVE, Sixth Product Usin...
06/18/2024 12:03:40

merck-shares-are-trading-higher-after-the-fda-approved-capvaxive-for-the-prevention-of-invasive-pneumococcal-disease-and-pneumococcal-pneumonia-in-adults
Merck shares are trading higher after the ...
06/18/2024 11:39:14

fda-approves-capvaxive-for-prevention-of-invasive-pneumococcal-disease-and-pneumococcal-pneumonia-in-adults
FDA Approves CAPVAXIVE For Prevention Of I...
06/17/2024 21:31:48

CAPVAXIVE (V116) is specifically designed for adults and covers serotypes responsible for approximately 84% of invasive pneumoc...

fda-approves-mercks-keytruda-plus-carboplatin-paclitaxel-as-treatment-for-adult-patients-with-primary-advanced-or-recurrent-endometrial-carcinoma
FDA Approves Merck's KEYTRUDA Plus Carbopl...
06/17/2024 21:15:49

KEYTRUDA is now the first and only anti-PD-1 therapy FDA-approved in combination with chemotherapy for adult patients with prim...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

06/28/2024 Malibu Boats, Inc. (MBUU)
07/01/2024 Globe Life Inc. f/k/a Torchmark Corporation (GL)
07/01/2024 Equinix, Inc. (EQIX)
07/02/2024 Intel Corporation (INTC)
07/05/2024 AXT, Inc. (AXTI)
07/05/2024 Altimmune, Inc. (ALT)
07/09/2024 Li Auto Inc. (LI)
07/12/2024 Inari Medical, Inc. (NARI)
07/12/2024 Sprout Social, Inc. (SPT)
07/15/2024 UnitedHealth Group Inc. (UNH)

NEW CASE INVESTIGATION

Ooma Inc (OOMA) AnaptysBio Inc (ANAB)